Dec 08, 2015

GNS Healthcare Secures $10M Series C Financing to Accelerate Development of New, Data-Driven Solutions at the Intersection of Precision Medicine and Population Health

New Investors Celgene Corporation, Alexandria Real Estate Equities, and Gi Global Health Fund LP Join Cambia Health Solutions, Heritage Provider Network, Mitsui

CAMBRIDGE, Mass. – Dec. 8, 2015 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, today announced the completion of a $10M Series C financing round. New investors in this round are Celgene Corporation, Alexandria Real Estate Equities, and Gi Global Health Fund LP. These three new investors join prior investors, including Cambia Health Solutions, California’s Heritage Provider Network, and Japan’s Mitsui & Co. U.S. subsidiary (“Mitsui USA”).

The financing will be used to accelerate the development of new, cloud-based big data solutions at the intersection of precision medicine and population health. GNS solutions leverage the company’s patented causal machine learning and simulation platform, REFS™ (Reverse Engineering and Forward Simulation), to unlock value from increasingly rich streams of patient data, including data from electronic medical records, mobile health devices, medical and pharmacy claims, genomics, consumer behavior, and more. GNS solutions better match drugs and other health interventions to individual patients, improving outcomes and lowering costs related to preterm birth; medication non-adherence; metabolic syndrome; comparative effectiveness in diabetes, specialty care and oncology; end-of-life care; new member risk on healthcare exchanges; patient stratification in clinical trials; and more. GNS licenses its solutions to health plans, pharmaceutical companies, healthcare providers, foundations, academic research organizations, and self-insured employers. These solutions rapidly deliver actionable insights to guide researchers, inform clinical decisions by healthcare leaders, and to support patient-physician conversations at the point of care.

“As a trailblazer in precision medicine and a leader of an emerging movement to connect precision medicine to mainstream medicine, GNS Healthcare is well-positioned in this high-impact, high-growth market,” said Drs. Mireille and Dennis Gillings of Gi Global Health Fund LP.

The application of precision medicine to population health makes it possible to know, in advance, which interventions will work for specific individuals and to achieve a positive return on population health investments. This breakthrough approach improves health outcomes, reduces costs for individuals and populations, and drives the discovery of new drugs and health interventions. GNS has been at the forefront of the precision medicine movement since 2000, pioneering big data solutions in a range of complex conditions and costly, persistent healthcare challenges.

“Machine learning can reveal cause-and-effect relationships in data, not just patterns and correlations, making it possible – and practical – to predict many future “what if” scenarios, to compare outcomes across different treatments, patient by patient, and ultimately use that knowledge to optimize treatment decisions,” said Colin Hill, CEO and co-founder of GNS. “We’re honored to work with world-class pioneers as investors and partners in our quest to transform healthcare.”

About GNS Healthcare
GNS Healthcare applies causal machine learning technology to predict which treatments will work for which patients, improving individual patient outcomes and the health of populations, while reducing costs. The GNS technology is based on its MAX™ (Meaningful Actions Accelerator) data integration architecture and patented REFS™ (Reverse Engineering and Forward Simulation) causal inference and simulation engine. Health plans, bio-pharmaceutical companies, healthcare providers, foundations, academic medical centers, and employers use these cloud-based solutions to solve pressing and costly problems, including preterm birth, end-of-life care, comparative effectiveness, medication non-adherence, metabolic syndrome, diabetes, specialty care medications, drug target discovery, patient stratification in clinical trials, and more. GNS solutions focus on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness through precision matching that maximizes impact on individual patient health outcomes while reducing wasteful spending and downstream medical costs.

GNS Healthcare, Driving Intelligent Interventions

Media Contact

Gina Veazey